Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Joanne B.L. Tan"'
Autor:
Matthew J. Walters, Kelsey E. Sivick, Uli Schindler, Jay P. Powers, Stephen W. Young, Jaroslaw Kalisiak, Nikki Kimura, Timothy W. Park, Bhamini Purandare, Susan L. Paprcka, Fangfang Yin, Akshata R. Udyavar, Elaine Ginn, Ada Chen, Kristen Zhang, Daniel DiRenzo, Nell Narasappa, Jesus Banuelos, Annette Becker, Joanne B.L. Tan, Dana Piovesan
Supplementary Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eb5b5a4e6987b75f7ac46778faa4a20
https://doi.org/10.1158/1535-7163.22522347
https://doi.org/10.1158/1535-7163.22522347
Autor:
Matthew J. Walters, Kelsey E. Sivick, Uli Schindler, Jay P. Powers, Stephen W. Young, Jaroslaw Kalisiak, Nikki Kimura, Timothy W. Park, Bhamini Purandare, Susan L. Paprcka, Fangfang Yin, Akshata R. Udyavar, Elaine Ginn, Ada Chen, Kristen Zhang, Daniel DiRenzo, Nell Narasappa, Jesus Banuelos, Annette Becker, Joanne B.L. Tan, Dana Piovesan
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35adf1efc1bd618059ec8b92f7b406e6
https://doi.org/10.1158/1535-7163.22522341
https://doi.org/10.1158/1535-7163.22522341
Autor:
Matthew J. Walters, Kelsey E. Sivick, Uli Schindler, Jay P. Powers, Stephen W. Young, Jaroslaw Kalisiak, Nikki Kimura, Timothy W. Park, Bhamini Purandare, Susan L. Paprcka, Fangfang Yin, Akshata R. Udyavar, Elaine Ginn, Ada Chen, Kristen Zhang, Daniel DiRenzo, Nell Narasappa, Jesus Banuelos, Annette Becker, Joanne B.L. Tan, Dana Piovesan
T cells play a critical role in the control of cancer. The development of immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed in only a subs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db083be516cf4170981d0503a34a58b
https://doi.org/10.1158/1535-7163.c.6543339.v1
https://doi.org/10.1158/1535-7163.c.6543339.v1
Autor:
Dana Piovesan, Joanne B.L. Tan, Annette Becker, Jesus Banuelos, Nell Narasappa, Daniel DiRenzo, Kristen Zhang, Ada Chen, Elaine Ginn, Akshata R. Udyavar, Fangfang Yin, Susan L. Paprcka, Bhamini Purandare, Timothy W. Park, Nikki Kimura, Jaroslaw Kalisiak, Stephen W. Young, Jay P. Powers, Uli Schindler, Kelsey E. Sivick, Matthew J. Walters
Publikováno v:
Molecular Cancer Therapeutics. 21:948-959
T cells play a critical role in the control of cancer. The development of immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed in only a subs
Autor:
Brandon Reid Rosen, Manmohan Reddy Leleti, Ada Chen, Sharon Zhao, Jenna L. Jeffrey, Norbert Sträter, Eric T. Newcomb, Jay P. Powers, Kenneth V. Lawson, Lijuan Fu, Dillon H. Miles, Uli Schindler, Wade Berry, Stephen W Young, Tim Park, Emma Scaletti, Lixia Jin, Joanne B.L. Tan, Ehesan U. Sharif, Laurent Debien, Erick Allen Lindsey, Jaroslaw Kalisiak, Susanne Moschütz, Matthew J. Walters, Guifen Xu, Nigel Walker
Publikováno v:
Journal of Medicinal Chemistry. 63:11448-11468
Extracellular adenosine (ADO), present in high concentrations in the tumor microenvironment (TME), suppresses immune function via inhibition of T cell and NK cell activation. Intratumoral generation of ADO depends on the sequential catabolism of ATP
Autor:
Steven C. Katz, Chandra C. Ghosh, Prajna Guha, Joanne B.L. Tan, Louis F. Chai, Kara R. Heatherton, Sarah Wadsworth, Nafees Rahman, James B. Trager, Denise Gonzalez
Publikováno v:
Journal of Clinical Oncology. 38:e15016-e15016
e15016 Background: Colorectal cancer liver metastases (CRCLM) are a major source of morbidity and mortality. Historically, curative therapy has been limited to surgical resection, but only a small fraction of patients are eligible. Cellular immunothe
Autor:
Manmohan Reddy Leleti, Joanne B.L. Tan, Devika Ashok, Jay P. Powers, Steve Young, Daniel DiRenzo, Matthew J. Walters, Park Adam, Dana Piovesan, Nell Narasappa, Lisa Seitz, Jenna L. Jeffrey
Publikováno v:
Cancer Immunology Research. 8:A10-A10
Introduction: High levels of immunosuppressive adenosine are found in the tumor microenvironment, reaching 50-100 μM in experimental models. Adenosine exerts its effects on immune cells primarily through the adenosine receptors A2aR/A2bR, which incr
Autor:
Akshata Udyavar, Matthew J. Walters, Joanne B.L. Tan, Woosuk Kim, Caius G. Radu, Luyi Li, Arthur E. Cho, Thuc Le, Daniel DiRenzo, Brandon Reid Rosen
Publikováno v:
Cancer Immunology Research. 8:A46-A46
Background: CD73 catalyzes the extracellular generation of adenosine (ADO) from adenosine monophosphate (AMP). High levels of ADO, found in the tumor microenvironment (TME), have been shown to suppress immune responses and curtail T-cell activation i
Autor:
Gerhard Arold, Joanne B.L. Tan, Manmohan Reddy Leleti, Jenna L. Jeffrey, Devika Ashok, Renger G. Tiessen, Aimee Rieger, Lisa Seitz, Matthew J. Walters, Jay P. Powers, Joyson Joseph Karakunnel, Lixia Jin
Publikováno v:
Investigational new drugs. 37(4)
Adenosine suppresses antitumor immune responses via A2a and A2b receptors expressed on intratumoral immune cells. This effect is mediated by increased cyclic adenosine 5′-monophosphate (AMP) levels and phosphorylation of cyclic AMP response element
Autor:
Lisa Seitz, Rick Stanton, Joanne B.L. Tan, Amy E. Anderson, Fang-Fang Yin, Xiaoning Zhao, Nigel Walker, Hema Singh, Annette Becker
Publikováno v:
Cancer Immunology Research. 7:A124-A124
TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor that is expressed on natural killer (NK) cells, CD8+ T-cells, and immunosuppressive regulatory T-cells (Treg). DNAM-1 (DNAX Accessory Molecule-1; CD226) is an activating